Effects of night eating during simulated shift work on metabolism, cognitive performance and mood in healthy adult males

Not Applicable

Completed

• Conditions: Cognitive performance; Metabolic health; Diet and Nutrition - Other diet and nutrition disorders; Mental Health - Studies of normal psychology, cognitive function and behaviour; Metabolic and Endocrine - Normal metabolism and endocrine development and function

• Registration Number: ACTRN12615001107516
• Lead Sponsor: Dr Siobhan Banks

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 12

Inclusion Criteria

Males, aged 18-45 years, BMI normal to overweight (20-29kg/m2), non-smoker, low alcohol (less than or equal to 2 standard drinks/ day) and caffeine consumption (less than or equal to 2 cups/ day), normal sleep/wake pattern (habitual sleep duration between 7-8 hours a night), stable weight over the preceding 3 months, competent written and spoken English.

Exclusion Criteria

Subjects who report one or more of the following: habitual napping (more than 1 per week), score of less than 31 or more than 69 in the morningness- eveningness questionnaire, significant depression or physical illness, established using clinical history and Beck Depression Inventory (score equal to or more than 14), food difficulties (example: gluten intolerance or restrained eaters) measured by clinical history, use of medications, including injected, topical or inhaled glucocorticoids, previous shift work history, sleep disorders, history of medical conditions; cardiovascular disease, neurological disorder, kidney disease, liver disease, clinically significant values (as determined by the reviewing study physician) for any hematology or chemistry parameter. Reviewing study licensed physician may opt to repeat any clinically significant tests and include volunteers whose repeat test values are not clinically significant, currently taking corticosteroid or anti-inflammatory medications.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum samples for glucose analysis will be collected to assess markers of metabolic risk at regular intervals pre and post breakfast.[-15, 0 minutes pre- and 15, 30, 60, 90 and 120 minutes post-breakfast on days 1 (baseline), 4 and 5 (recovery).];-Serum samples for insulin analysis will be collected to assess markers of metabolic risk at regular intervals pre and post breakfast.[-15, 0 minutes pre- and 15, 30, 60, 90 and 120 minutes post-breakfast on days 1 (baseline), 4 and 5 (recovery).];Serum samples for free fatty acid analysis will be collected to assess markers of metabolic risk at regular intervals pre and post breakfast.[-15, 0 minutes pre- and 15, 30, 60, 90 and 120 minutes post-breakfast on days 1 (baseline), 4 and 5 (recovery).]

Secondary Outcome Measures

Name	Time	Method
Cognitive functioning, assessed by a battery of cognitive tests including: psychomotor vigilance task (vigilant attention task), and Digit-symbol substitution task [Every 3-hours during wake periods on Day 2- Day 5. An additional time point will be added on Day 1 (baseline) and Day 6 (post recovery sleep).];Markers of sleep quality will be assessed using polysomnography. Some markers of sleep quality are total sleep time, sleep efficiency and slow wave sleep. [Day 1 (baseline), Day 4 and Day 6 (recovery)];Mood, assessed by a battery of cognitive tests including: Likert type scales and PANAS [Every 3-hours during wake periods on Day 2- Day 5. An additional time point will be added on Day 1 (baseline) and Day 6 (post recovery sleep).]